David Amsellem
Stock Analyst at Piper Sandler
(4.71)
# 226
Out of 4,840 analysts
144
Total ratings
59.32%
Success rate
30.16%
Average return
Main Sectors:
Stocks Rated by David Amsellem
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| AMGN Amgen | Maintains: Overweight | $329 → $328 | $271.66 | +20.74% | 3 | May 16, 2025 | |
| OGN Organon & Co. | Maintains: Overweight | $24 → $18 | $8.69 | +107.13% | 6 | May 15, 2025 | |
| COLL Collegium Pharmaceutical | Reiterates: Neutral | $36 → $37 | $28.89 | +28.07% | 8 | May 9, 2025 | |
| JAZZ Jazz Pharmaceuticals | Reiterates: Overweight | $176 → $147 | $108.07 | +36.02% | 14 | May 7, 2025 | |
| NBIX Neurocrine Biosciences | Reiterates: Overweight | $160 → $154 | $120.18 | +28.14% | 10 | May 6, 2025 | |
| BMY Bristol-Myers Squibb Company | Initiates: Overweight | $65 | $46.85 | +38.74% | 1 | Apr 22, 2025 | |
| CORT Corcept Therapeutics | Maintains: Overweight | $128 → $131 | $78.69 | +66.48% | 7 | Apr 3, 2025 | |
| AMPH Amphastar Pharmaceuticals | Maintains: Neutral | $36 → $32 | $24.47 | +30.77% | 8 | Mar 21, 2025 | |
| XERS Xeris Biopharma Holdings | Reiterates: Neutral | $3 → $4 | $4.83 | -17.18% | 5 | Mar 7, 2025 | |
| INDV Indivior | Maintains: Overweight | $16 → $13 | $11.26 | +15.45% | 5 | Mar 6, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Neutral | $14 → $10 | $8.29 | +20.63% | 7 | Mar 5, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $23 → $30 | $16.96 | +76.89% | 10 | Jan 17, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $24 → $13 | $9.13 | +42.39% | 5 | Jan 10, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $26 → $9 | $6.53 | +37.83% | 1 | Jan 2, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $9 → $11 | $7.16 | +53.74% | 4 | Nov 11, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Overweight | $38 → $37 | $29.35 | +26.06% | 7 | Oct 25, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Overweight | $68 | $57.81 | +17.63% | 1 | Oct 11, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Neutral | $41 → $36 | $32.11 | +12.11% | 15 | Sep 11, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Underweight | $9 → $3 | $4.45 | -32.58% | 7 | Aug 2, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $42 | $25.82 | +62.66% | 10 | Jul 3, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Overweight | $10 | $2.35 | +325.53% | 1 | Apr 11, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $20 → $21 | $0.57 | +3,608.28% | 3 | Feb 16, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $90 → $113 | $105.07 | +7.55% | 3 | Jan 16, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $72 → $42 | $34.17 | +22.91% | 3 | Oct 16, 2023 |
Amgen
May 16, 2025
Maintains: Overweight
Price Target: $329 → $328
Current: $271.66
Upside: +20.74%
Organon & Co.
May 15, 2025
Maintains: Overweight
Price Target: $24 → $18
Current: $8.69
Upside: +107.13%
Collegium Pharmaceutical
May 9, 2025
Reiterates: Neutral
Price Target: $36 → $37
Current: $28.89
Upside: +28.07%
Jazz Pharmaceuticals
May 7, 2025
Reiterates: Overweight
Price Target: $176 → $147
Current: $108.07
Upside: +36.02%
Neurocrine Biosciences
May 6, 2025
Reiterates: Overweight
Price Target: $160 → $154
Current: $120.18
Upside: +28.14%
Bristol-Myers Squibb Company
Apr 22, 2025
Initiates: Overweight
Price Target: $65
Current: $46.85
Upside: +38.74%
Corcept Therapeutics
Apr 3, 2025
Maintains: Overweight
Price Target: $128 → $131
Current: $78.69
Upside: +66.48%
Amphastar Pharmaceuticals
Mar 21, 2025
Maintains: Neutral
Price Target: $36 → $32
Current: $24.47
Upside: +30.77%
Xeris Biopharma Holdings
Mar 7, 2025
Reiterates: Neutral
Price Target: $3 → $4
Current: $4.83
Upside: -17.18%
Indivior
Mar 6, 2025
Maintains: Overweight
Price Target: $16 → $13
Current: $11.26
Upside: +15.45%
Mar 5, 2025
Reiterates: Neutral
Price Target: $14 → $10
Current: $8.29
Upside: +20.63%
Jan 17, 2025
Maintains: Overweight
Price Target: $23 → $30
Current: $16.96
Upside: +76.89%
Jan 10, 2025
Maintains: Overweight
Price Target: $24 → $13
Current: $9.13
Upside: +42.39%
Jan 2, 2025
Maintains: Overweight
Price Target: $26 → $9
Current: $6.53
Upside: +37.83%
Nov 11, 2024
Maintains: Overweight
Price Target: $9 → $11
Current: $7.16
Upside: +53.74%
Oct 25, 2024
Reiterates: Overweight
Price Target: $38 → $37
Current: $29.35
Upside: +26.06%
Oct 11, 2024
Initiates: Overweight
Price Target: $68
Current: $57.81
Upside: +17.63%
Sep 11, 2024
Downgrades: Neutral
Price Target: $41 → $36
Current: $32.11
Upside: +12.11%
Aug 2, 2024
Downgrades: Underweight
Price Target: $9 → $3
Current: $4.45
Upside: -32.58%
Jul 3, 2024
Maintains: Overweight
Price Target: $42
Current: $25.82
Upside: +62.66%
Apr 11, 2024
Initiates: Overweight
Price Target: $10
Current: $2.35
Upside: +325.53%
Feb 16, 2024
Maintains: Overweight
Price Target: $20 → $21
Current: $0.57
Upside: +3,608.28%
Jan 16, 2024
Maintains: Overweight
Price Target: $90 → $113
Current: $105.07
Upside: +7.55%
Oct 16, 2023
Maintains: Overweight
Price Target: $72 → $42
Current: $34.17
Upside: +22.91%